Replies to post #3272 on Theriva Biologics Inc (TOVX)

[Seel]

No. 47% was year one only. We don't know % for combo group for year two. At least I don't think we know...I think the 32% is copaxone-only group for year two and the combo treatment group was higher than that but not significantly so.
This should not feel like we're translating a new and unknown language!!!! Frustrating as hell!

[pistol1p]

IMO:

At 12 months the reduction in the relapse rate, in the Trimesta plus Copaxone treatment group, was 47% lower than in the placebo plus Copaxone group. The P value, for statistical significance, was: <.05. Thus the 47% reduction was statistically significant, therefore the outcome is less likely to have happened by chance.

At 24 months the reduction in the relapse rate, in the Trimesta plus Copaxone treatment group, was 32% lower than in the placebo plus Copaxone group. The P value, for statistical significance, was: > .05. Thus the 32% reduction was not statistically significant, therefore it is unclear if the 32% reduction was an effect of the Trimesta, or was just a chance occurrence.